RPID
BEARISH
$2.28
Live
Rapid Micro Biosystems, Inc. · NASDAQ
Target $8.0
(+250.9%)
$2.01
52W Range
$4.94
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 19, 2026
Market cap
$104.35M
P/E
N/A
ROE
-86.8%
Profit margin
-140.3%
Debt/Equity
0.72
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
RPID exhibits severe fundamental weakness, highlighted by a weak Piotroski F-Score of 3/9 and a complete lack of profitability. While the company shows strong top-line revenue growth (37.3% YoY) and maintains a healthy current ratio (3.31), these are overshadowed by an abysmal gross margin of 3.12% and negative profit margins of -140.30%. The stark divergence between the 'Strong Buy' analyst consensus and the aggressive insider selling by the CEO, CFO, and COO suggests a significant disconnect between market expectations and internal sentiment.
Key Strengths
Strong YoY revenue growth of 37.30%
High liquidity with a current ratio of 3.31
Manageable debt-to-equity ratio of 0.72
Strong analyst target price ($8.00) relative to current price
Positive Q/Q revenue growth trend
Key Risks
Extremely low gross margins (3.12%) for the medical device industry
Severe negative profitability (Profit Margin: -140.30%)
Consistent failure to meet earnings estimates (0/4 beats in last 4 quarters)
Weak financial health as indicated by Piotroski F-Score (3/9)
Significant long-term price erosion (5Y Change: -89.3%)
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
22
Weak
20
45
15
30
0
AI Verdict
High Risk / Speculative
Key drivers: C-suite insider selling, Poor gross margins, Weak Piotroski score, Consistent earnings misses
Confidence
90%
Value
20/100
Ref P/E, PEG, Graham Number
Positives
- Low market cap provides high volatility potential
Watchpoints
- No P/E due to losses
- Price/Book of 3.05 is high for a non-profitable entity
- No Graham Number available
Future
45/100
Ref Growth rates
Positives
- Strong YoY revenue growth (37.3%)
- High analyst price targets
Watchpoints
- Negative EPS growth
- Inability to convert revenue to gross profit
Past
15/100
Ref Historical trends
Positives
- 3Y change shows a recovery spike (+115%)
Watchpoints
- 5Y change is -89.3%
- Chronic earnings misses over 20 quarters
Health
30/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Strong current and quick ratios
Watchpoints
- Piotroski F-Score of 3/9 indicates weak financial health
- Negative ROE and ROA
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- No history of payouts
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$2.28
Analyst Target
$8.0
Upside/Downside
+250.9%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for RPID and closest competitors.
Updated 2026-04-17
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
RPID
Rapid Micro Biosystems, Inc.
Primary
|
-89.3% | +115.1% | -5.0% | -26.0% | -14.9% | +7.5% |
|
IMDX
Insight Molecular Diagnostics Inc.
Peer
|
-97.0% | -53.0% | +9.3% | -18.5% | -39.6% | -15.7% |
|
KZIA
Kazia Therapeutics Limited
Peer
|
-98.5% | -84.8% | +141.6% | +26.4% | +8.8% | +20.2% |
|
MDXH
MDxHealth SA
Peer
|
-82.2% | -35.5% | +37.2% | -49.0% | -33.1% | +4.4% |
|
DH
Definitive Healthcare Corp.
Peer
|
-97.5% | -89.8% | -57.4% | -66.5% | -13.7% | -13.0% |
RPI
Rapid Micro Biosystems, Inc.
Primary
5Y
-89.3%
3Y
+115.1%
1Y
-5.0%
6M
-26.0%
1M
-14.9%
1W
+7.5%
IMD
Insight Molecular Diagnostics Inc.
Peer
5Y
-97.0%
3Y
-53.0%
1Y
+9.3%
6M
-18.5%
1M
-39.6%
1W
-15.7%
KZI
Kazia Therapeutics Limited
Peer
5Y
-98.5%
3Y
-84.8%
1Y
+141.6%
6M
+26.4%
1M
+8.8%
1W
+20.2%
MDX
MDxHealth SA
Peer
5Y
-82.2%
3Y
-35.5%
1Y
+37.2%
6M
-49.0%
1M
-33.1%
1W
+4.4%
DH
Definitive Healthcare Corp.
Peer
5Y
-97.5%
3Y
-89.8%
1Y
-57.4%
6M
-66.5%
1M
-13.7%
1W
-13.0%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-2.77
PEG Ratio
N/A
P/B Ratio
3.05
P/S Ratio
3.11
EV/Revenue
2.64
EV/EBITDA
-1.99
Market Cap
$104.35M
Profitability
Profit margins and return metrics
Profit Margin
-140.3%
Operating Margin
-108.23%
Gross Margin
3.12%
ROE
-86.82%
ROA
-34.24%
Growth
Revenue and earnings growth rates
Revenue Growth
+37.3%
Earnings Growth
N/A
Q/Q Revenue Growth
+3.08%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.72
Moderate
Current Ratio
3.31
Strong
Quick Ratio
2.27
Excellent
Cash/Share
$0.85
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q3 2025
Revenue
$0.0B
Gross Margin
8.9%
Op. Margin
-145.1%
Net Margin
-146.8%
Total Assets
$0.1B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
0.90x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
101%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-08
$N/A
2026-03-12
$-0.28
-23.5% surprise
2025-11-07
$-0.26
-6.1% surprise
2025-08-12
$-0.27
-6.6% surprise
Healthcare Sector Comparison
Comparing RPID against 447 companies in the Healthcare sector
(26 bullish, 140 neutral, 281 bearish)
Return on Equity (ROE)
-86.82%
This Stock
vs
-97.42%
Sector Avg
-10.9%
(Below Avg)
Profit Margin
-140.3%
This Stock
vs
-14.95%
Sector Avg
+838.5%
(Superior)
Debt to Equity
0.72
This Stock
vs
3.06
Sector Avg
-76.5%
(Less Debt)
Revenue Growth
37.3%
This Stock
vs
147.85%
Sector Avg
-74.8%
(Slower)
Current Ratio
3.31
This Stock
vs
4.68
Sector Avg
-29.2%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
RPID
Rapid Micro Biosystems, Inc.
|
BEARISH | $104.35M | - | -86.8% | -140.3% | $2.28 | |
|
IMDX
Insight Molecular Diagnostics Inc.
|
BEARISH | $101.97M | - | -% | -% | $3.17 | Compare |
|
KZIA
Kazia Therapeutics Limited
|
NEUTRAL | $100.79M | - | -106.9% | -% | $8.82 | Compare |
|
MDXH
MDxHealth SA
|
BEARISH | $109.92M | - | -2440.4% | -31.1% | $2.14 | Compare |
|
DH
Definitive Healthcare Corp.
|
NEUTRAL | $111.79M | - | -40.4% | -57.5% | $1.07 | Compare |
RPID
Rapid Micro...
BEARISH
Mkt Cap
$104M
P/E
-
ROE
-86.8%
Price
$2.28
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-11 | WIRTJES SEAN M. CPA | Chief Financial Officer | Sale | 7,480 | $32,299 |
| 2026-03-11 | WILSON JOHN J. ADDINGTON | Chief Operating Officer | Sale | 9,603 | $41,467 |
| 2026-03-10 | SPIGNESI ROBERT G JR | Chief Executive Officer | Sale | 17,922 | $73,686 |
| 2026-02-27 | RICCIARDI NATALE S | Director | Option Exercise | 842 | $632 |
| 2026-02-20 | WIRTJES SEAN M. CPA | Chief Financial Officer | Sale | 17,254 | $67,687 |
| 2026-02-20 | WILSON JOHN J. ADDINGTON | Chief Operating Officer | Sale | 5,403 | $21,196 |
| 2026-02-19 | SPIGNESI ROBERT G JR | Chief Executive Officer | Sale | 38,327 | $148,912 |
| 2026-02-11 | WIRTJES SEAN M. CPA | Chief Financial Officer | Stock Award | 97,000 | - |
| 2026-02-11 | WILSON JOHN J. ADDINGTON | Chief Operating Officer | Stock Award | 74,000 | - |
| 2026-02-11 | SPIGNESI ROBERT G JR | Chief Executive Officer | Stock Award | 264,000 | - |
| 2026-02-09 | WIRTJES SEAN M. CPA | Chief Financial Officer | Sale | 6,027 | $22,798 |
| 2026-02-09 | WILSON JOHN J. ADDINGTON | Chief Operating Officer | Sale | 4,610 | $17,438 |
| 2026-02-09 | SPIGNESI ROBERT G JR | Chief Executive Officer | Sale | 12,840 | $48,570 |
| 2026-02-04 | LONGITUDE CAPITAL PARTNERS II, LLC | Beneficial Owner of more than 10% of a Class of Security | Sale | 49,000 | $190,091 |
| 2026-02-03 | LONGITUDE CAPITAL PARTNERS II, LLC | Beneficial Owner of more than 10% of a Class of Security | Sale | 108,739 | $473,859 |
WIRTJES SEAN M. CPA
Chief Financial Officer
2026-03-11
7,480 shares
·
$32,299
WILSON JOHN J. ADDINGTON
Chief Operating Officer
2026-03-11
9,603 shares
·
$41,467
SPIGNESI ROBERT G JR
Chief Executive Officer
2026-03-10
17,922 shares
·
$73,686
RICCIARDI NATALE S
Director
2026-02-27
842 shares
·
$632
WIRTJES SEAN M. CPA
Chief Financial Officer
2026-02-20
17,254 shares
·
$67,687
WILSON JOHN J. ADDINGTON
Chief Operating Officer
2026-02-20
5,403 shares
·
$21,196
SPIGNESI ROBERT G JR
Chief Executive Officer
2026-02-19
38,327 shares
·
$148,912
WIRTJES SEAN M. CPA
Chief Financial Officer
2026-02-11
97,000 shares
WILSON JOHN J. ADDINGTON
Chief Operating Officer
2026-02-11
74,000 shares
SPIGNESI ROBERT G JR
Chief Executive Officer
2026-02-11
264,000 shares
WIRTJES SEAN M. CPA
Chief Financial Officer
2026-02-09
6,027 shares
·
$22,798
WILSON JOHN J. ADDINGTON
Chief Operating Officer
2026-02-09
4,610 shares
·
$17,438
SPIGNESI ROBERT G JR
Chief Executive Officer
2026-02-09
12,840 shares
·
$48,570
LONGITUDE CAPITAL PARTNERS II, LLC
Beneficial Owner of more than 10% of a Class of Security
2026-02-04
49,000 shares
·
$190,091
LONGITUDE CAPITAL PARTNERS II, LLC
Beneficial Owner of more than 10% of a Class of Security
2026-02-03
108,739 shares
·
$473,859
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
DEF 14A
10-K
10-Q
8-K
10-Q
RPID has expanded its commercial footprint through a February 2025 distribution agreement with Millipore S.A.S. and the integration of its Growth Direct system with Lonza’s MODA-EM module. Key risks include uncertainty regarding whether these integrations will drive broader market adoption and the potential for Lonza to collaborate with competitors, which may limit future sales growth.
8-K
Data sourced from SEC EDGAR. AI summaries generated automatically.
Past News Coverage
Recent headlines mentioning RPID from our newsroom.
Newest → oldest
No matching news yet.